MRK Earnings Date: Feb 2, 2027 (Estimated) — Merck & Co., Inc.
NYSE · Healthcare · Drug Manufacturers - General
Updated
When is MRK's next earnings date?
Merck & Co., Inc. (MRK) is expected to report Q4 2026 earnings on Tuesday, February 2, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.95 on revenue of $16.90B.
How did MRK do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Merck & Co., Inc. posted EPS of $2.49 versus the $2.09 estimate, a beat of 19.1%. Revenue was $18.09B against a $17.33B estimate. The stock's 1-day post-earnings move was +3.8%.
How much does MRK stock move after earnings?
MRK beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.5% (up or down) in the day after earnings.
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
🤖 AI Earnings Analysis
Merck’s Q3 beat was strong, with revenue up 4.6% to $18.1B and EPS of $2.49, despite a year-over-year EPS decline. 2026 guidance implies continued scale, but growth quality warrants scrutiny.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 2.09 | 2.49 | +19.14% | $18.09B | ✅ Beat | +3.83% | — | — |
| 2026-08-04 | Q2 2026 | 0.23 | -0.13 | -156.52% | $16.61B | ❌ Miss | +0.18% | +2.46% | +17.29% |
| 2026-04-30 | Q1 2026 | -1.48 | -1.28 | +13.51% | $16.29B | ✅ Beat | -1.60% | +2.36% | +7.00% |
| 2026-02-03 | Q4 2025 | 2.02 | 2.04 | +0.99% | $16.40B | ✅ Beat | +2.18% | +3.77% | +6.09% |
| 2025-10-30 | Q3 2025 | 2.35 | 2.58 | +9.79% | $17.28B | ✅ Beat | -0.34% | -2.53% | +21.08% |
| 2025-07-29 | Q2 2025 | 2.01 | 2.13 | +5.97% | $15.81B | ✅ Beat | -1.69% | -5.00% | +1.11% |
| 2025-04-24 | Q1 2025 | 2.14 | 2.22 | +3.74% | $15.53B | ✅ Beat | +1.40% | +8.21% | -1.13% |
| 2025-02-04 | Q4 2024 | 1.68 | 1.72 | +2.38% | $15.62B | ✅ Beat | -9.07% | -13.41% | -6.61% |
Showing last 8 quarters.